No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PCRX240719C37500
- 0.55
- 0.000.00%
15min DelayTrading May 23 12:01 ET
0.00High0.00Low
0.00Open0.55Pre Close0 Volume1 Open Interest37.50Strike Price0.00Turnover223.03%IV82.19%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier14DDays to Expiry0.55Extrinsic Value100Contract SizeAmericanOptions Type0.1393Delta0.0238Gamma37.97Leverage Ratio-0.0709Theta0.0009Rho5.29Eff Leverage0.0093Vega
Intraday
- 5D
- Daily
News
Pacira BioSciences, Inc.'s (NASDAQ:PCRX) 30% Dip In Price Shows Sentiment Is Matching Revenues
Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders won't be pleased to see that the share price has had a very rough month, dropping 30% and undoing the prior period's positive performance. The dr
Pacira Downgraded at Barclays Following Generic Exparel Approval
This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Pacira BioSciences Price Target Maintained With a $42.00/Share by Piper Sandler
Pacira BioSciences Price Target Maintained With a $42.00/Share by Piper Sandler
Express News | Piper Sandler Maintains Overweight on Pacira BioSciences, Maintains $42 Price Target
Truist Financial Maintains Pacira BioSciences(PCRX.US) With Buy Rating
Truist Financial analyst Les Sulewski maintains $Pacira BioSciences(PCRX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 59.5% and a total average return of 9.4% o
Comments
Recent insider share sale and lack of insider buying in the past year may concern investors. Despite some alignment between management and smaller shareholders, caution is advised due to recent insider selling activity.
Pacira BioSciences Independent Director Gary Pace Sells 85% Of Holding 1
Pacira BioSciences' moderate net income growth is seen as a positive despite a low ROE. The growth could be due to good management decisions or a low payout ratio, as it doesn't pay dividends. Analysts predict future earnings momentum.
1
Multiple insiders selling shares over the past year could be a red flag. However, insider ownership level shows alignment between management and smaller shareholders. Lack of insider purchases in the past year calls for caution.
The market seems to tolerate EPS decline but last year's worse-than-average performance may indicate long term investor concerns.
$Pacira BioSciences(PCRX.US$ $Flexion Therapeutics Inc(FLXN.US$ On October 12, Pacira BioSciences announced that it has entered into a definitive agreement to acquire Flexion Therapeutics For $8.50 per share, or approximately $430 million, in cash to enhance its non-opioid pain portfolio. The deal also includes contingent valuable rights worth up to $8.00 per share, which are tied to Zilretta sales targets and FDA approvals for FX201 and FX301.
3
Read more